ADC Therapeutics (ADCT) investor relations material

Strategic overview and trial rationale

• ZYNLONTA aims to expand from third-line plus to earlier lines in DLBCL and LBCL, targeting both complex and broadly accessible treatment segments.

• LOTIS-7 is a Phase 1b trial combining ZYNLONTA with glofitamab, a bispecific antibody, in second-line plus DLBCL and other LBCL subtypes, hypothesizing additive or synergistic efficacy and manageable safety.

• The trial design includes dose escalation and expansion, with primary endpoints of safety, tolerability, and recommended dose, and secondary endpoints of efficacy, PK, immunogenicity, DOR, PFS, and OS.

• The combination is positioned to potentially double the addressable patient population and increase therapy duration and market share.

• Dose expansion is ongoing at 150 mcg/kg ZYNLONTA plus glofitamab, targeting approximately 100 patients.

Patient population and study design

• 49 efficacy-evaluable patients with r/r LBCL, median age 70 (range 26–85), 59% male, 51% with high LDH, and 51% refractory to last prior therapy.

• The study included patients with large B-cell lymphoma subtypes, including those previously treated with CAR-T (16%) and SCT (6%), and those with double/triple hit lymphoma (16%).

• Median prior lines of therapy was one (range 1–5); 61% had only one prior line.

• The 150 mcg/kg dose is being used for ongoing enrollment.

Efficacy results

• ORR was 89.8% (44/49), with a CR rate of 77.6% (38/49); 33/38 CRs were ongoing at data cutoff.

• Median time to response was 42 days; 14 patients converted from SD/PR to CR over time.

• In relapsed patients, ORR was 100% and CR rate 92%; in primary refractory patients, ORR was 80% and CR rate 64%.

• Of eight patients previously treated with CAR-T, six achieved CR.

• The longest response observed exceeded 18 months.